What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective

AIDS

Volumn 13, Issue 8, 1999, Pages 873-881

  Hu, Dale J ^a   Buvé, Anne ^b   Baggs, James ^c   Van der Groen, Guido ^b   Dondero, Timothy J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c EDS   (United States)

Author keywords

Epidemiology; Genotypes; HIV 1; HIV 2; Pathogenesis; Strain; Subtypes; Transmissibility

Indexed keywords

DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; VIRUS TYPING;

DISEASE PROGRESSION; EPIDEMIOLOGY, MOLECULAR; HIV INFECTIONS; HIV-1; HUMANS; VARIATION (GENETICS);

EID: 0032966973     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905280-00002     Document Type: Review

References (120)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
2. Hu DJ, Dondero TJ, Rayfield MA, et al. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA 1996, 275:210-216.
3. Clavel F, Guetard D, Brun-Vezinet F, et al. Isolation of a new retrovirus from west African patients with AIDS. Science 1986, 233:343-346.
4. DeCock KM, Adjorlolo-Johnson G, Ekpini E, et al. Epidemiology and transmission of HIV-2 Why there is no HIV-2 pandemic? JAMA 1993, 270:2083-2086.
5. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987, 4:406-425.
6. Li WH. A statistical test of phylogenies estimated from sequence data. Mol Biol Evol 1987, 6:424-435.
7. Hillis DM, Huelsenbeck JP, Cunningham CW. Application and accuracy of molecular phylogenies. Science 1994, 264:671-677.
8. Human Retroviruses and AIDS 1992. Los Alamos: Los Alamos National Laboratory; 1992.
9. Human Retroviruses and AIDS 1994. Los Alamos: Los Alamos National Laboratory; 1994.
10. Gao F, Yue L, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994, 68:7433-7447.
11. European Commission (DG XII JDJUNPoHA) and the Joint United Nations Programme on HIV/AIDS. HIV-subtypes: implications for epidemiology, pathogenicity, vaccines, and diagnostics. AIDS 1997, 11:UNAIDS17-UNAIDS36.
12. Janssens W, Buve A, Nkengasong JN. The puzzle of HIV-1 subtypes in Africa. AIDS 1997, 11:705-712.
13. Rothman KJ. Modern Epidemiology. Boston: Little, Brown, and Company; 1986.
14. Elwood JM. Critical Appraisal of Epidemiological Studies and Clinical Trials, 2nd edn. Oxford: Oxford University Press; 1998.
15. Kleinbaum DG, Kupper LL, Margenstern H. Epidemiologic Research, New York: Van Nostrand Reinhold; 1982.
16. Mastro ID, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS 1996, 10 (suppl A):S75-S82.
17. Hu DJ, Dondero TJ, Mastro TD, Gayle HD. Global and molecular epidemiology of HIV. In: AIDS and Other Manifestations of HIV Infection. 3rd edn. Edited by Wormser GP. Philadelphia: Lippincott-Raven Publishers; 1998:27-40.
18. WHO Network for HIV Isolation and Characterization. HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. AIDS Res Hum Retroviruses 1994, 10:1327-1343.
19. Artenstein AW, VanCott TC, Mascola JR, et al. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis 1995, 171:805-810.
20. Pieniazek D, Janini LM, Ramos A, et al. HIV-1 patients may harbor viruses of different phylogenetic subtypes: implications for the evolution of the HIV/AIDS pandemic. Emerg Infect Dis 1995, 1:86-88.
21. Hu WS, Temin HM. Retroviral recombination and reverse transcription. Science 1990, 250:1227-1233.
22. Robertson DL, Sharp PM, McCutchan FE, Hahn BH. Recombination in HIV-1 [letter]. Nature 1995, 374:124-126.
23. Murphy E, Korber B, Georges-Courbot MC, et al. Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the Central African Republic. AIDS Res Hum Retroviruses 1993, 9:997-1006.
24. Orloff GM, Kalish ML, Chiphangwi J, et al. V3 loops of HIV-1 specimens from pregnant women in Malawi uniformly lack a potential N-Linked glycosylation site. AIDS Res Hum Retroviruses 1993, 9:705-706.
25. Nkengasong JN, Janssens W, Heyndrickx L, et al. Genotypic subtypes of HIV-1 in Cameroon, AIDS 1994, 8:1405-1412.
26. Janssens W, Heyndrickx L, Fransen K, et al. Genetic and phylogenetic analysis of env subtypes G and H in Central Africa. AIDS Res Hum Retroviruses 1994, 10:877-879.
27. Delaporte E, Janssens W, Peeters M, et al. Epidemiological and molecular characteristics of HIV infection in Gabon, 1986-1994, AIDS 1996, 10:903-910.
28. Simon F, Mauclere P, Roques P, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nature Med 1998, 4:1032-1037.
29. Ou CY, Takebe Y, Luo CC, et al. Wide distribution of two subtypes of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992, 8:1471-1472.
30. Ou CY, Takebe Y, Weniger BG, et al. Independent introduction of two major HIV-1 genotypes into two distinct high-risk populations in Thailand, Lancet 1993, 341:1171-1174.
31. Pau CP, Lee-Thomas S, Wattana A, et al. Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS 1993, 7:337-340.
32. U.S.Bureau of the Census. HIV/AIDS in Asia. 3rd International Conference on AIDS in Asia and the Pacific. Chiang Mai, Thailand, September 1995 [research note No. 18].
33. Weniger BG, Limpakarnjanarat K, Ungchusak K, et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS 1991, 5:S71-S85.
34. Wasi C, Herring B, Raktham S, et al. Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. AIDS 1995, 9:843-849.
35. Solo-Ramirez LE, Renjifo B, McLane MF, et al. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 1996, 271:1291-1293.
36. O'Brien TR, Polon C, Schable CA, et al. HIV-2 infection in an American. AIDS 1991, 5:85-88.
37. Centers for Disease Control and Prevention. Update: HIV-2 infection among blood and plasma donors - United States, June 1992-June 1995. MMWR 1995, 44:603-606.
38. Artenstein AW, Coppola J, Brown AE, et al. Multiple introductions of HIV-1 subtype E into the western hemisphere. [Published erratum appears in Lancet 1995, 346:1376]. Lancet 1995, 346:1197-1198.
39. Brodine SK, Mascola JR, Weiss PJ, et al. Detection of diverse HIV-1 genetic subtypes in the USA. Lancet 1995, 346:1190-1199.
40. Gao F, Yue L, Hill SC, et al. HIV-1 sequence subtype D in the United States. AIDS Res Hum Retroviruses 1994, 10:625-627.
41. M serotypes in French blood donors over a 10-year period (1983-1995). AIDS 1997, 11:1503-1508.
42. Sonnerborg A, Durdevic S, Giesecke J, Sallberg M. Dynamics of the HIV-1 subtype distribution in the Swedish HIV-1 epidemic during the period 1980 to 1993. AIDS Res Hum Retroviruses 1997, 13:343-345.
43. Dietrich U, Ruppach H, Gehring S, et al. Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors [letter]. AIDS 1997, 11:1532-1533.
44. Arnold C, Barlow KL, Kaye S, Loveday C, Balfe P, Clewley JP. HIV type 1 sequence subtype G transmission from mother to infant: failure of variant sequence species to amplify in the Roche Amplicor Test. AIDS Res Hum Retroviruses 1995, 11:999-1001.
45. Salminen M, Nykanen A, Brummer-Korvenkontio H, Kantanen ML, Liitsola, Leinikki P. Molecular epidemiology of HIV-1 based on phylogenetic analysis of in vivo gag p7/p9 direct sequences. Virology 1993, 195:185-194.
46. Fransen K, Buvé A, Nkengasong JN, Laga M, van der Groen G, Longstanding presence in Belgians of multiple non-B HIV-1 subtypes. Lancet 1996, 347:1403-1403.
47. Morganstern H. Uses of ecologic analysis in epidemiologic research. Am J Public Health 1982, 72:1336.
48. Morris M, Kretzschmar M. Concurrent partnerships and the spread of HIV. AIDS 1997, 11:641-648.
49. Laga M, Nzila N, Goeman J. The interrelationship of sexually transmitted diseases and HIV infection: implications for the control of both epidemics in Africa. AIDS 1991, 5(suppl 1):S55-S63.
50. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of STDs on HIV infection in rural Tanzania: randomized controlled trial. Lancet 1995, 346:530-536.
51. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women, Nature Med 1995, 1:59-64.
52. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection of Caucasian individuals bearing mutant alleles of the CCr5 chemokine receptor gene. Nature 1996, 382:722-725.
53. Biti R, French R, Young J, Benneth B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nature Med 1997, 3:252-253.
54. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 delta32 (Letter). Lancet 1997, 343:1219-1219.
55. Theodorou I, Meyer L, Magierowska M, Kadama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Lancet 1997, 319:1219-1220.
56. Poulsen AG, Kvinesdal B, Aaby P, et al. Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet 1989, i:827-831.
57. Gnaore E, DeCock KM, Gayle H, et al. Prevalence of and mortality from HIV type 2 in Guinea Bissau, West Africa. Lancet 1989, ii:513-513.
58. Kanki PJ, Travers KU, Mboup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994, 343:943-946.
59. Andreasson PA, Dias F, Naucler A, Andersson S, Biberfeld G. A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 1993, 7:989-993.
60. The HIV Infection in Newborns French Collaborative Study Group. Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. Pediatr Infect Dis J 1994, 13:502-506.
61. Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994, 272:462-466.
62. Oxtoby MI. Perinatally acquired human immunodeficiency virus infection, [Review]. Pediatr Infect Dis J 1990, 9:609-619.
63. European Collaborative Study. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991, 337:253-260.
64. Halsey NA, Boulos R, Holt E, et al. Transmission of HIV-1 infections from mothers to infants in Haiti. Impact on childhood mortality and malnutrition. JAMA 1990, 264:2088-2092.
65. Mastro TD, Satten GA, Nopkesorn T, Sangkharomya S, Longini IM. Probability of female-to-male transmission of HIV-1 in Thailand. Lancet 1994, 343:204-207.
66. Cameron DW, Simonsen JN, D'Costa IJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989, 2:403-407.
67. Shaffer N, Roongpisuthipong A, Siriwasin, et al. Maternal viral load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. J Infect Dis 1999, 179:590-599.
68. Kunanusont C, Foy HM, Kreiss JK, et al. HIV-1 subtypes and male-to-female transmission in Thailand. Lancet 1995, 345:1078-1083.
69. Graziosi C, Soudeyns H, Rizzardini GP, Bart PA, Chapuis A, Pantaleo G. Immunopathogenesis of HIV infection. AIDS Res Hum Retroviruses 1918, 14(suppl 2):S133-S142.
70. Fauci A. Host factors and the pathogenesis of HIV-induced disease. Nature 1996, 384:329-534.
71. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996, 271:324-328.
72. Pepin J, Morgan G, Dunn D, et al. HIV-2 induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1. AIDS 1991, 5:1165-1172.
73. Kestens L, Brattegaard K, Adjorlolo G, et al. Immunological comparison of HIV-1, HIV-2 and dually-reactive women delivering in Abidjan, Côte d'lvoire. AIDS 1992, 6:803-807.
74. Whittle H, Morris J, Todd J, et al. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS 1994, 8:1617-1620.
75. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994, 265:1587-1590.
76. Friedland GH, Saltzman B, Vileno J, Freeman K, Schrager LK, Klein RS. Survival difference in patients with AIDS. J Acquir Immun Defic Syndr Hum Retrovirol 1991, 4:144-153.
77. Gardner LI, Brundage JF, McNeil JG, et al. Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army natural history cohort. J Acquir Immun Defic Syndr Hum Retrovirol 1992, 5:782-793.
78. Hessol NA, Koblin BA, van Griensven GJ, et al. Progression of HIV-1 infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco. Am J Epidemiol 1994, 139:1077-1087.
79. Hu DJ, Fleming PL, Castro KG, et al. How important is race/ethnicity as an indicator of risk for specific AIDS-defining conditions? J Acquir Immun Defic Syndr Hum Retrovirol 1995, 10:374-380.
80. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332:201-208.
81. Kaplan JE, Hu DJ, Holmes KK, Jaffe HW, Masur H, De Cock KM. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Am J Trop Med Hyg 1996, 55:1-11.
82. Anzala AO, Nagelkerke NJ, Bwayo JJ, et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995, 171:686-689.
83. Morgan D, Maude G, Malamba SS, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet 1997, 350:245-250.
84. Chequer P, Hearst N, Hudes ES, et al. Determinants of survival in adult Brazilian AIDS patients, 1982-1989. AIDS 1992, 6:483-487.
85. Kitayaporn D, Tansuphaswadikul S, Lohsomboon P, et al. Survival of AIDS patients in the emerging epidemic in Bangkok, Thailand. J Acquir Immun Defic Syndr Hum Retrovirol 1996, 11:77-82.
86. Hu DJ, Byers RJ, Fleming PL, Ward JW. Characteristics of persons with late AIDS diagnosis in the United States. Am J Prevent Med 1995, 11:114-119.
87. Limpakarnjanarat K, Tansuphaswadikul S, Mastro TD, et al. Clinical presentation, risk category, and HIV-1 subtypes B and E in 1241 HIV/AIDS patients in Thailand. XIth International Conference on AIDS. Vancouver, July 1996.
88. Weniger BG, Tansuphaswadikul S, Young NL, et al. Differences in immune function among patients infected with distinct Thailand HIV-1 strains. X International Conference on AIDS. Yokohama, Japan, August 1994 [abstract 012C].
89. Amornkul PN, Tansuphaswadikul S, Limpakarnjanarat K, et al. HIV-1 subtypes B′ and E: Associated clinical, immunologic, and risk characteristics in Bangkok, Thailand. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 711].
90. Low N, Paine K, Clark R, Mahalingam M, Pozniak AL. AIDS survival and progression in black Africans living in south London, 1986-1994. Genitourin Med 1996, 72:12-16.
91. Petruckevitch A, Del Amo J, Phillips A, et al. Survival and CD4+ lymphocyte decline in HIV-infected Africans and non-Africans in London. XIth International Conference on AIDS. Vancouver, July 1996 [abstract We.B.3337].
92. Lasky M, Perret JL, Peeters M, et al. The impact of the HIV-1 genetic subtype on the natural history of HIV-1 infection: preliminary results. XIth International Conference on AIDS. Vancouver, July 1996 [abstract Tu.A.20G0].
93. Kaleebu P, Morgan D, Ross A, et al. Relationship between immunological progression in HIV-1 infection and viral subtypes in a well characterised cohort in Uganda. X International Conference on AIDS and STD in Africa. Abidjan, Africa, December 1997 [abstract A02.3].
94. Kanki P, Hamel D, Sankale JL, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999, 179:58-73.
95. Galai N, Kalinkovich A, Burstein R, Vlahov D, Bentwich Z. African HIV-1 subtype C and rate of progression among Ethiopian immigrants in Israel [letter]. Lancet 1997, 349:180-181.
96. Mastro ID, Vanichseni S, Kitayaporn D, et al. Viral load and CD4/CD8 cell count in injecting drug users (IDUs) newly infected wilh HIV-1 subtypes B′ and E, Bangkok. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 275].
97. Clapham PR, Blanc D, Weiss RA. Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. Virology 1991, 181:703-715.
98. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996, 381:661-667.
99. Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997, 71:7478-7487.
100. Kwong PD, Wyalt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
101. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Med 1997, 3:1259-1265.
102. McNicholl JM, Smith DK, Qari SH, Hodge T. Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele (Delta32 CCR5). Emerg Infect Dis 1997, 3:261-271.
103. Ischerning C, Alaeus A, Fredriksson R, et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998, 241:181-188.
104. Pope M, Frankel SS, Mascola JR, et al. Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. J Virol 1997, 71:8001-8007.
105. Dittmar MI, Simmons G, Hibbitts S, et al. Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups. J Virol 1997, 71:8000-8013.
106. Cocchi E, Gallo RC, Garzino-Demo A, Cara A, Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockage of infection. Nature Med 1996, 270:1811-1815.
107. Lersmette M, Lange JMA, de Goede RE, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989, i:983-985.
108. De Wolf F, Hogervorst E, Goudsmit J, et al. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterisation. AIDS Res Hum Retroviruses 1914, 10:1387-1400.
109. Zhong P, Peeters M, Janssens W, et al. Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D. AIDS Res Hum Retroviruses 1995, 11:239-248.
110. Rubsamen-Waigmann H, von Briesen H, Holmes H, et al. Standard conditions of virus isolation reveal biological variability of HIV type 1 in different regions of the world. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1904, 10: 1401-1408.
111. Essex M, Soto-Ramirez LE, Renjilo B, Wang WK, Lee T. Genetic variation within human immunodeficiency virus generates rapid changes in tropism, virulence, and transmission. leukemia 1997, 11:93-94.
112. cpz is reflected in the genetic diversity that distinguishes them. AIDS Res Hum Retroviruses 1997, 13: 7-17.
113. Zhang Y, Fracasso C, Fiore JR, et al. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1 infected long-term nonprogressors. J Infect Dis 1997, 176:1180-1187.
114. Korber B. HIV molecular immunology database. 1996. Part 1. Los Alamos: Los Alamos National Laboratory, Theoretical Biology and Biophysics; 1996.
115. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996, 70:427-444.
116. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996, 70:445-458.
117. Nyambi PN, Nkengasong J, Lewi P, et al. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 1996, 70:6235-6243.
118. Cao H, Kanki P, Sankale JL, Korber B, M'Boup S, Walker BD. CTL cross-reactivity among different HIV-1 clades: implications for vaccine development. J Virol 1997, 71:8615-8623.
119. Korber B. HIV variability and CTL epitopes. Workshop on HIV-1 Subtypes; Implications for Epidemiology, Pathogenicity, Vacciness, and Diagnostics. Dar es Salaam, Tanzania, June 1997.
120. van der Groen G, Nyambi P, Beirnaerl E, et al. Genetic variation of HIV type 1: relevance of interclade variation to vaccine development. AIDS Res Hum Retroviruses 1998, 14 (suppl 3):S211-S221.